Exact Mass: 487.1743

Exact Mass Matches: 487.1743

Found 22 metabolites which its exact mass value is equals to given mass value 487.1743, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

YC 170

3-Pyridinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-2,6-dimethyl-5-((phenylamino)carbonyl)-, 2-(2-pyridinyl)ethyl ester

C28H26ClN3O3 (487.1663)


   

stesakine-9-O-beta-D-glucopyranoside

stesakine-9-O-beta-D-glucopyranoside

C25H29NO9 (487.1842)


   

spiruchostatin B

spiruchostatin B

C21H33N3O6S2 (487.1811)


A spiruchostatin with molecular formula C21H33N3O6S2 originally isolated from a Pseudomonas culture broth. D004791 - Enzyme Inhibitors > D056572 - Histone Deacetylase Inhibitors

   
   

4-hydroxy-3-methoxyphenylacetonitrile 4-O-beta-D-glucopyranosyl(1->6)-beta-D-glucopyranoside|adenophoraside B

4-hydroxy-3-methoxyphenylacetonitrile 4-O-beta-D-glucopyranosyl(1->6)-beta-D-glucopyranoside|adenophoraside B

C21H29NO12 (487.169)


   

Trp-HoPhe-OH

(S)-2-(3-(2-(1H-indol-3-yl)ethoxy)-4-nitrobenzamido)-5-phenylpentanoic acid

C27H25N3O6 (487.1743)


   

Fmoc-3-(9-anthryl)-L-Alanine

Fmoc-3-(9-anthryl)-L-Alanine

C32H25NO4 (487.1783)


   

Fmoc-D-Anthrylalanine

Fmoc-D-Anthrylalanine

C32H25NO4 (487.1783)


   

Dacomitinib monohydrate

Dacomitinib monohydrate

C24H27ClFN5O3 (487.1786)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

   

N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[N-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-methylanilino]acetamide

N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[N-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-methylanilino]acetamide

C24H29N3O6S (487.1777)


   

(2R,3S,3aS,5R,6R,7S,9aS)-5-[(2R,3E,5E,7E)-7-(2,4-dioxopyrrolidin-3-ylidene)-4-methyl-7-oxidohepta-3,5-dien-2-yl]-2,6,9a-trimethyl-8-oxooctahydro-3a,7-epoxyfuro[3,2-b]oxocine-3-carboxylate

(2R,3S,3aS,5R,6R,7S,9aS)-5-[(2R,3E,5E,7E)-7-(2,4-dioxopyrrolidin-3-ylidene)-4-methyl-7-oxidohepta-3,5-dien-2-yl]-2,6,9a-trimethyl-8-oxooctahydro-3a,7-epoxyfuro[3,2-b]oxocine-3-carboxylate

C25H29NO9-2 (487.1842)


   

(2S,3S,3aR,9bR)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

(2S,3S,3aR,9bR)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

C24H29N3O6S (487.1777)


   

(2S,3S,3aR,9bR)-N-cyclobutyl-3-(hydroxymethyl)-7-(4-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

(2S,3S,3aR,9bR)-N-cyclobutyl-3-(hydroxymethyl)-7-(4-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

C24H29N3O6S (487.1777)


   

(1R,9S,10S,11S)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-5-(3-methoxyphenyl)-12-methylsulfonyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

(1R,9S,10S,11S)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-5-(3-methoxyphenyl)-12-methylsulfonyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

C24H29N3O6S (487.1777)


   

(2R,3R,3aS,9bS)-N-cyclobutyl-3-(hydroxymethyl)-7-(4-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

(2R,3R,3aS,9bS)-N-cyclobutyl-3-(hydroxymethyl)-7-(4-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

C24H29N3O6S (487.1777)


   

(1S,9R,10R,11R)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-5-(3-methoxyphenyl)-12-methylsulfonyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

(1S,9R,10R,11R)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-5-(3-methoxyphenyl)-12-methylsulfonyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

C24H29N3O6S (487.1777)


   

(2R,3R,3aS,9bS)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

(2R,3R,3aS,9bS)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-1-methylsulfonyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

C24H29N3O6S (487.1777)


   

[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] nonanoate

[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] nonanoate

C19H30N5O8P (487.1832)


   

nocamycin E(2-)

nocamycin E(2-)

C25H29NO9 (487.1842)


A monocarboxylic acid anion that is a dianion resulting from the deprotonation of the carboxy group and the enol group of nocamycin E. The major species at pH 7.3.

   

AZD-8529

AZD-8529

C24H24F3N5O3 (487.1831)


AZD-8529 is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2, with an EC50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes.

   

(9s,15e,20r)-5,8,18,21-tetrahydroxy-20-methyl-6-(sec-butyl)-2-oxa-11,12-dithia-7,19,22-triazabicyclo[7.7.6]docosa-7,15,18,21-tetraen-3-one

(9s,15e,20r)-5,8,18,21-tetrahydroxy-20-methyl-6-(sec-butyl)-2-oxa-11,12-dithia-7,19,22-triazabicyclo[7.7.6]docosa-7,15,18,21-tetraen-3-one

C21H33N3O6S2 (487.1811)


   

5,8,18,21-tetrahydroxy-20-methyl-6-(sec-butyl)-2-oxa-11,12-dithia-7,19,22-triazabicyclo[7.7.6]docosa-7,15,18,21-tetraen-3-one

5,8,18,21-tetrahydroxy-20-methyl-6-(sec-butyl)-2-oxa-11,12-dithia-7,19,22-triazabicyclo[7.7.6]docosa-7,15,18,21-tetraen-3-one

C21H33N3O6S2 (487.1811)